NCT03779750 is a clinical trial of s.creatinine in End Stage Renal Disease Patients, sponsored by Assiut University.

Who is sponsoring NCT03779750?

NCT03779750 is sponsored by Assiut University.

What drugs are being tested in NCT03779750?

Interventions in NCT03779750: s.creatinine.

What condition does NCT03779750 study?

NCT03779750 studies End Stage Renal Disease Patients.

Is NCT03779750 still recruiting?

NCT03779750 is currently status unknown. Last updated 19 December 2018.

Last reviewed 2018-12-19 · How we verify

NCT03779750

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Causes Of End Stage Renal Disease In Patients Undergoing Regular Hemodialysis

Status unknown Last updated 19 December 2018

What this trial tests

trial testing s.creatinine in End Stage Renal Disease Patients in 200 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
1 December 2020

1 March 2021

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 January 2019
Primary completion	1 December 2020
Estimated completion	1 March 2021
Sites	2 locations across Egypt

Drugs / interventions tested

s.creatinine

Conditions studied

End Stage Renal Disease Patients — all drugs for End Stage Renal Disease Patients →

Sponsor

Assiut University

Who can join

18 and older, any sex, with End Stage Renal Disease Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CKD is defined as kidney damage for ≥3 months, as defined by structural and or functional abnormalities of the kidney, with or without decreased GFR or GFR \<60 mL/min/1.73m2 for ≥3 months, with or without kidney damage. CKD is classified based on cause, GFR category, and albuminuria category (CGA). ESRD has become a public health problem worldwide, with recent reports showing that the total number of ESRD patients has been growing dramatically.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03779750 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 19 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03779750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing